TMO — Thermo Fisher Scientific Income Statement
0.000.00%
Last trade - 00:00
- $233.46bn
- $260.15bn
- $42.86bn
- 95
- 18
- 94
- 78
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 25,542 | 32,218 | 39,211 | 44,915 | 42,857 |
Cost of Revenue | |||||
Gross Profit | 11,329 | 15,987 | 19,638 | 18,971 | 17,100 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 21,132 | 24,424 | 29,950 | 36,548 | 35,998 |
Operating Profit | 4,410 | 7,794 | 9,261 | 8,367 | 6,859 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 4,070 | 7,225 | 8,841 | 7,835 | 6,298 |
Provision for Income Taxes | |||||
Net Income After Taxes | 3,704 | 6,375 | 7,732 | 7,132 | 6,014 |
Minority Interest | |||||
Equity in Affiliates | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | 3,696 | 6,375 | 7,725 | 6,950 | 5,995 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 3,696 | 6,375 | 7,725 | 6,950 | 5,995 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 8.85 | 16.2 | 21.9 | 18 | 16.7 |
Dividends per Share |